P1390: The Efficacy and Safety of Modified Melphalan and Busulfan-Based Regimen for Allogeneic Transplantation in Refractory/Relapsed Aml Patients

Chen, S.; Zhang, X.; Zhai, Weihua; He, Yi; Feng, Sizhou; Han, Mingzhe; Niu, Ting; Xu, Yuming; Gao, Guo; Fan, Shengjin; Zhou, Zhang Ping; Zhou, Fubiao; Li, F.; Liu, L.; Yang, Wenping; Liu, Q.; Zhang, X.; Jiang, Erlie

doi:10.1097/01.hs9.0000848420.57492.c3

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2022

2023

Publication Types

Select...

Preprint1

Article1

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Post-HSCT maintenance treatment using entrectinib for an AML patient accompanied ETV6-NTRK3: a case report

Zhao

Hao

Zhang

et al. 2022

Preprint

View full text Add to dashboard Cite

The neurotrophic receptor tyrosine kinases (NTRKs) gene fusions occur in many different tumors, and tropomyosin receptor kinase (TRK) inhibitors exhibit attractive antitumor activity. This case report presents that a patient with refractory AML accompanied ETV6-NTRK3 was failed in traditional chemotherapy, then received continue remission after hematopoietic stem cell transplantation (HSCT) and maintenance therapy with entrectinib. This is the first time that TRK inhibitor has been used in patient with AML after HSCT.

show abstract